Drug Database
TE

teriparatide (Xinfutai)

✓ Approved

Shenzhen Salubris Pharmaceuticals Co., Ltd. · PTH1R · Recombinant Proteins

What is teriparatide?

teriparatide is a recombinant proteins developed by Shenzhen Salubris Pharmaceuticals Co., Ltd.. It is approved for therapeutic indications via injectable (others) or subcutaneous injection.

Drug Profile

Brand NamesXinfutai
CompanyShenzhen Salubris Pharmaceuticals Co., Ltd.
Drug ClassRecombinant Proteins
Molecular TargetPTH1R
RouteInjectable (Others), Subcutaneous Injection
StatusApproved
Sources: ClinicalTrials.gov, Shenzhen Salubris Pharmaceuticals Co., Ltd.

Mechanism of Action

Molecular Targets

teriparatide acts on 1 molecular target:

PTH1Rparathyroid hormone 1 receptor (PTHR, EKNS)
Want deeper analysis?Noah AI can explain complex mechanisms and compare to similar drugs.

Therapeutic Indications

teriparatide is developed for 1 unique indication across 1 therapeutic area.

Therapeutic AreaConditionPhase
Musculoskeletal and connective tissue disordersOsteoporosis✓ Approved

Related Research Articles

PubMedHealthcare quarterly (Toronto, Ont.)2026-08-30

Addressing Canada's Pharmaceutical Research and Development Intensity Gap: The Role of Health Data Transformation.

Mullie Thomas T, Chuck Anderson A

The life sciences industry, and specifically the pharmaceutical sub-sector, is a major funder of private sector research and development. Canada's life sciences industry reinvests less of its revenues in research and development (R&D) activities than those in peer countries, which hinders innovation, creates supply risks and contributes to Canada's poor productivity growth. Traditional approaches to incentivizing reinvestment, including tax incentives, direct funding and public research spending, have failed. As an alternative, transforming Canada's health data systems would enable faster and more comprehensive secondary use, making R&D investments safer and more productive. Our peers are already pursuing this strategy, meaning Canada risks being left behind unless we act.

PMID 42669639
Read full article →
PubMedExploratory research in clinical and social pharmacy2026-08-30

In defence of the drug, two hearts, one profession: Reintegrating medicines expertise and patient-centred care in pharmacy's professional identity.

Davies Neal M NM

For more than three decades, pharmacy has narrated its evolution as a movement away from the product and toward the patient. The pharmaceutical care era ushered in by Hepler and Strand in 1990 framed dispensing and product expertise as a chrysalis the profession needed to shed in order to mature. That framing has been useful, but it has also been misread, and the misreading has now been institutionalised. Some accreditation councils, regulatory and licensing bodies, and advocacy bodies have positioned the profession as one moving away from a so-called "product centric" past. The thesis of this commentary is otherwise. Pharmacy has never had a single heart; it has always had two, one beating for the drug and the other for the patient, and they have always beaten in the same chest, for four centuries and more. The pharmacist's claim to a place at the patient's bedside rests entirely on what the pharmacist knows about the molecule: medicinal chemistry, pharmaceutics, compounding, biopharmaceutics, pharmacokinetics, pharmacogenomics, radiopharmacy, pharmacognosy and now pharmaceutical artificial intelligence. The argument here is not nostalgic but expansive. Embrace them all. Without the drug, the diagnosis is a verdict, not a treatment; and without the pharmacist, no drug appears.

PMID 42668522
Read full article →
PubMedChemistry, an Asian journal2026-08-30

Rapid Transformation of Carcinogenic 4-Nitrophenol by Nanoparticles Synthesized Using Recycled Copper Waste: A Sustainable Circular Economic Approach.

Kumar Virender V, Kumar Ravi R, Kumar Gyanendra G, Masram Dhanraj T DT et al.

Novel Cu/Cu2O-nanoparticles have been synthesized by the most economical electrochemical method utilizing metallic waste. 4-NP is a toxic pollutant affecting both animal and plant kingdom, necessitating its elimination from environment. This study demonstrates that the prepared nano-catalysts efficiently catalyse the reduction of 4-nitrophenol (4-NP) to 4-aminophenol (4-AP) at room temperature under light condition. Further, the reduction process generates amine derivatives, which are intermediates in many industrial processes. This manuscript adheres to the principles of the circular economy by generating nanoparticles through the repurposing of metallic waste discarded by both industry and domestic users. Using scrapped copper from discarded air conditioner (AC) copper tubes as electrodes, we employed an electrochemical technique to develop Cu/Cu2O nanoparticles. The synthesized nanoparticles were characterized using field emission scanning electron microscopy (FE-SEM), transmission electron (TEM), EDX spectroscopy, powder x-ray diffraction (P-XRD), Fourier transformation infrared (FTIR) spectroscopy, x-ray photoelectron spectroscopy (XPS), Raman spectroscopy, cyclic voltammetry (CV), and Brunauer-Emmett-Teller (BET) analysis. Our study confirms 99% conversion of harmful 4-NP to 4-AP in a rapid reaction time of 5 min. Synthesized nanoparticles can be reused up to four times without losing catalytic activity. UV-vis spectroscopy demonstrated that reduction follows pseudo-second-order kinetics and adsorption follows Freundlich isotherm model.

PMID 42668400
Read full article →
PubMedDrug delivery and translational research2026-08-30

Biodegradable furylacryloyl-modified hyaluronan: in vivo evaluation and its use as a nanofibrous drug delivery system.

Brtková Barbora B, Bártová Tereza T, Piskláková Lenka L, Šimek Matěj M et al.

Furylacryloyl-modified hyaluronan (F-HA) has emerged as an appropriate material for the fabrication of UV-crosslinkable, water-stable nanofibrous scaffolds with preserved porosity. However, the safety profile and in vivo applicability of F-HA have not yet been established. In this study, we present biological assessment of F-HA, including biodegradation studies and its first in vivo evaluation in C57BL/6J mice following both intravenous and intraperitoneal administration. The results demonstrate good tolerability under the tested conditions and confirm biodegradability. Additionally, we confirm the ability of composite nanofibers consisting of F-HA with established nanofiber-forming polymers, to incorporate active pharmaceutical ingredients (API), while retaining their porous structure and favorable mechanical properties. Importantly, the incorporation of F-HA alters the release profile of embedded API. Using octenidine dihydrochloride (OCT) as a model compound, we demonstrate sustained release from F-HA/lauroyl hyaluronan (L-HA) nanofibrous scaffolds in biologically relevant protein-containing media, while retaining its structural integrity, thus supporting its suitability for biomedical applications. These findings highlight the potential of F-HA as a versatile platform for the development of advanced nanofibrous biomaterials with translational relevance in topical wound healing and drug delivery.

PMID 42668347
Read full article →
PubMedmAbs2026-08-30

Quantifying molecular specificity in excipient-driven antibody solubilization.

Han Zexiang Z, Erkamp Nadia A NA, Scrutton Rob R, Licari Giuseppe G et al.

Excipients are widely used to suppress the self-association of therapeutic proteins, yet their mechanisms of action are not well understood and often assumed to be nonspecific. Here we show that excipient-mediated solubilization of therapeutic antibodies is markedly molecularly specific. Using a high-throughput combinatorial droplet microfluidic platform, we systematically quantify the effects of common pharmaceutical excipients across a diverse panel of monoclonal antibodies (mAbs). Although all studied excipients enhance solubility, their effects can vary significantly between antibodies, spanning dynamic ranges from approximately 7-fold to over 200-fold. Integrating experimental solubilization measurements with sequence- and structure-derived molecular descriptors, we identify interpretable physicochemical determinants underlying excipient responses; for example, the histidine effect is strongly dependent on mAb dipole moment. Our findings reveal trends that highlight the molecular specificity and complexity of antibody-excipient interactions, as well as the limitations of purely generic formulation rules. Overall, this study provides a quantitative framework for analyzing excipient effects across diverse antibodies and supports the development of predictive approaches for rational formulation design. The integration of high-throughput experimentation with molecular feature analysis offers a foundation for improving our understanding and prediction of antibody-specific formulation behavior.

PMID 42668421
Read full article →
PubMedDrug development and industrial pharmacy2026-08-30

Development of Extended-Release Oral Dosage Forms of Salbutamol Sulfate Using the Hot-Melt Extrusion Manufacturing Technique.

Ramadan Banan B, Al-Zoubi Nizar N, Migdadi Eman E, AlSuwais Alia Kh AK et al.

To fabricate and characterize extrudable polymeric matrices using a combination of ethyl cellulose (EC) and two different grades of hydroxypropyl cellulose (HPC) that can provide sustained drug release of the model drug salbutamol sulfate. Implementation of the Hot-Melt Extrusion (HME) technique in the fabrication of polymeric combinations that will provide ready-to-use matrices for sustained release dosage forms. Two formulation groups were developed; each with six formulations. The first group contained EC: HPC 370,000 ratios ranging from 55.52:13.8% to 6.9:62.46%, respectively. The second group contained EC: HPC 80,000 ranging from 59.4:10% to 9.4:60%, respectively. The release profiles were determined via in vitro studies to assess the ability of matrices to prolong salbutamol release. Solid-state characterization was also performed on the raw material and representative extrudates formulations using differential scanning calorimetry (DSC) and X-ray powder diffraction (XRPD) and polarized light microscopy (PLM). The first group formulations exhibited prolonged drug release profiles that accelerated progressively as the level of HPC 370,000 increased. In contrast, the second group formulations exhibited a noticeably faster release, demonstrating that HPC 80,000 can effectively accelerate drug release through enhanced matrix erosion and water penetration. DSC and XRPD revealed that the model drug remained in its stable crystalline state even after thermal processing via HME. PLM further confirmed drug crystallinity within the extrudates. EC-HPC matrices successfully demonstrated the feasibility of using HME to prepare sustained-release matrices for salbutamol sulfate with the ability to tune drug release by varying polymer grade and ratio.

PMID 42669207
Read full article →

+9996 more articles available with a free account

Sign up free to view all articles →

Ask about teriparatide